Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

METABOLIC SIGNALERInvestigationalPopular · Mitochondrial

MOTS-c

Mitochondrial-Derived Peptide · 10mg

Vial size

Status

Investigational

Route

SubQ

Half-life

~1-2 hours plasma

Class

Mitochondrial-derived peptide

WADA

Prohibited (S2, 2024)

MechanismAMPK Activation / Mitochondrial Homeostasis

Cohort76 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$75 USD/vial

À-la-carte: $85 USD/vial · Save 12%

Vials per allocation

Member total (1×)$75

À-la-carte total$85

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Mitochondrial-encoded peptide regulating systemic metabolic signaling, insulin sensitivity, and exercise capacity at the cellular level.

Mitochondrial-Derived Peptide · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Used inV-Series

V-04

Cellular - Energy & Longevity

Popular · Longevity & Cellular

MOTS-c · Metabolic Signaler

◆ Certificate of Analysis · MOTS-c

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Batch 001 · lot VL-MTC-2026-07A

Every 100 units are drawn from one lot and tested once. The certificate below is the one that applies to this batch - when it closes, the next opens with a new lot and a new certificate.

Lot · MOTS-C-2026-07-30

98.643%

Labeled

10 mg

Actual (HPLC)

9.56 mg

Method

HPLC + MS

Tested

Jul 30, 2026

Endotoxin

Heavy metals

not tested for this lot

Verify independently at janoshik.com/verificationPurity - code R2GZV78VN74LEndotoxin - code B6JXR7JPGIJ4

◉

Clinical Overview

MOTS-c

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA. It functions as a metabolic regulator that travels from the mitochondrion to the nucleus to modulate gene expression in response to metabolic stress.

✦

AMPK Activation

Mitochondrial-derived peptide; activates the AMPK energy pathway.

❤

Metabolic Signaling

Exercise-mimetic effects on glucose uptake and fat oxidation (preclinical).

❖

Mitochondrial Support

Modulates mitochondrial biogenesis signaling.

◈

Mechanism

How It Works

Activates AMPK pathway, regulates insulin sensitivity, and modulates mitochondrial biogenesis. Acts as a metabolic exercise mimetic with broad effects on glucose homeostasis and lipid metabolism.

Structural vs. signaling - how this peptide acts

MOTS-c works by signaling rather than by physical repair: it clears from the blood within about two hours, but during that window it can travel into the cell nucleus (within ~30 minutes) and adjust how stress-response and metabolic genes are expressed - prompting the cell to build and tune its own energy capacity over time. Think of it as sending instructions rather than fixing parts. (Contrast with SS-31, which acts structurally.) Its effects are adaptive and accrue gradually; timing, cycling, and duration are physician decisions, and Vivre does not publish a fixed schedule.

✚

Patient Bloodwork Guide

Bloodwork for Longevity & Mitochondrial Protocols

Cellular / mitochondrial - SS-31, MOTS-c, Epithalon, NAD+, V-04

These protocols target cellular energy, mitochondrial function, and markers of biological aging. Monitoring here is less about week-to-week safety and more about confirming the protocol is moving the deeper markers it is meant to.

Incremental approach. V-04 is introduced in phases (structural support first, then signaling, then a short telomere overlay) at conservative doses. Re-testing at the 6-month mark is how progress is judged.

Biological-age markers

Horvath methylation clockAn epigenetic estimate of biological age - the headline longevity marker, retested over months.

Telomere lengthTracks cellular aging at the chromosome level.

Mitochondrial & oxidative

Lactate (fasting & post-exercise)Healthy mitochondria clear lactate quickly. A high or slow-clearing level suggests cells are leaning on less-efficient anaerobic energy; a downward trend over time points to improving mitochondrial efficiency.

Lipid-peroxidation markers (MDA, 4-HNE)Signals of oxidative damage to cell membranes. Relevant to SS-31, which works by protecting the mitochondrial membrane lipid (cardiolipin) - a fall in these markers is a sign that structural protection is taking hold.

Fasting insulin & HOMA-IRA measure of how efficiently muscle takes up glucose. Relevant to MOTS-c, which supports muscle glucose uptake via the AMPK pathway - improvement shows as lower fasting insulin and a lower HOMA-IR score.

8-OHdGA marker of oxidative stress / DNA damage.

CoQ10A cofactor your mitochondria use to move electrons and produce energy.

Functional capacity

VO₂max / Zone-2 thresholdThe functional read-out of mitochondrial fitness - measured during graded exercise testing. As mitochondria adapt, the point where your body shifts from burning fat to burning carbohydrate moves, reflecting better aerobic capacity. A physical metric, not a blood test.

Routine safety

Fasting glucose & CMPStandard metabolic and organ-function checks.

When the tests happen

BaselineHorvath clock, telomere length, 8-OHdG, CoQ10, lactate/pyruvate, CMP.

Through the protocolSymptom and energy tracking; routine glucose/CMP.

Month 6Repeat Horvath clock + key markers to judge progress.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Mitochondrial-derived peptide (16 aa)
Studied mechanism	Metabolic regulation, AMPK-pathway activity in preclinical models
Human pharmacokinetics	Not well-characterised in human literature
Evidence base	Predominantly preclinical; early human interest
Form	Lyophilized powder, reconstituted under clinical protocol
Regulatory status	Not an approved therapy; physician-supervised use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Mechanism preclinical; human PK not established. Educational only.

Clinical Literature

Peer-Reviewed References

The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance

Lee C, Zeng J, Drew BG, et al. · 2015 · Cell Metabolism 2015;21:443–454

▾

Findings

Foundational discovery paper from the Cohen lab at USC. Identified MOTS-c as a mitochondrially-encoded peptide that activates AMPK signalling, improves insulin sensitivity in high-fat-diet mouse models, and reduces diet-induced obesity. Established MOTS-c as a metabolic-homeostasis regulator and the first widely-studied mitochondrially-derived peptide (MDP). Findings are preclinical (mouse); controlled human outcome trials for exogenous MOTS-c administration remain pending.

View on publisher ↗

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

Reynolds JC, Lai RW, Woodhead JST, et al. · 2021 · Nature Communications 2021;12:470

▾

Findings

In mice, late-life intermittent MOTS-c treatment (initiated at 23.5 months) increased physical capacity and healthspan markers. In humans, the authors demonstrated that exercise induces endogenous MOTS-c expression in skeletal muscle and circulation - supporting MOTS-c as an exercise-mimetic mitokine. The healthspan extension data are preclinical (mouse); the human findings are correlative (exercise induces endogenous MOTS-c), not yet outcome trials for exogenous administration.

View on publisher ↗

Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors

Dieli-Conwright CM, Sami N, Norris MK, et al. · 2021 · Scientific Reports 2021;11:16916

▾

Findings

Small human study (n=49) examining endogenous MOTS-c response to combined aerobic and resistance exercise across two ethnic groups. Post-exercise MOTS-c levels rose significantly in non-Hispanic White breast cancer survivors but not in Hispanic survivors, suggesting that endogenous MOTS-c response to exercise may be modulated by ethnic-specific mtDNA variation. Important context: this is endogenous-expression research, not a trial of exogenous MOTS-c therapy. Underlines that mechanism-to-clinic translation for exogenous MOTS-c administration is still pending.

View on publisher ↗

MOTS-c is an investigational compound with strong preclinical evidence in metabolic and aging contexts (Lee 2015, Reynolds 2021) and emerging human exercise-physiology research (Dieli-Conwright 2021). Controlled human outcome trials for exogenous MOTS-c administration are not yet published. Important disclosure for competitive athletes: MOTS-c is on the World Anti-Doping Agency Prohibited List from 2024 (S2 - peptide hormones and mimetics). At Vivre, MOTS-c is allocated under physician supervision with explicit informed consent that addresses both its investigational evidence status and its WADA status for any patient who competes in regulated sport.

◇

Clinical Applications

Indications

Mitochondrial dysfunction
Metabolic flexibility restoration
Component of longevity protocols (V-04)
Insulin resistance refractory to lifestyle intervention

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~1-2 hours plasma (estimated from exercise-induced clearance; ADDF Cognitive Vitality review). Biological effects on AMPK signaling and mitochondrial biogenesis persist 24-72 hours or longer after plasma clearance.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Strong preclinical research base in metabolic and longevity research. Limited but growing human clinical data.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

▣

Featured In

V-Series Protocols Including MOTS-c

◎

Commonly Paired

Compounds Often Prescribed With MOTS-c

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Mitochondrial Protectant

SS-31

Elamipretide · 10mg

◆ mitochondrial pair

MOTS-c and SS-31 address mitochondrial health from two complementary directions - MOTS-c via metabolic signalling (AMPK activation, biogenesis, the "exercise-mimetic" pathway) and SS-31 structurally (cardiolipin binding, inner-membrane/cristae stabilisation, reduced electron leak). Both are components of the V-04 longevity protocol. Note: the combination rationale is mechanistic - there is no combination-outcome trial; suitability is a physician determination.

View SS-31 detail →

Pineal Regulator

Epithalon

Tetrapeptide · 10mg

◆ longevity pair

MOTS-c and Epithalon address mitochondrial energetics and pineal-circadian regulation respectively - the primary longevity pairing in Vivre's V-04 protocol.

View Epithalon detail →

READY TO PROCEED

Start with the Biological Audit

MOTS-c is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$75 USD/vial

MOTS-c · Member rate